TP53 and therapy-related myeloid neoplasm: After adjustment for demographic and clinical factors, our analysis suggested that pre-aHSCT cases with dominant or co-dominant mutations affecting PPM1D (12.9 vs. 2.0%, P = 0.05) and TP53 (9.7 vs. 0%, P = 0.02) were more likely to be present in patients subsequently developing tMN (Supplementary Fig. S7).